Drug Detail:Quazepam (Quazepam [ kway-ze-pam ])
Drug Class: Benzodiazepines
Usual Adult Dose for Insomnia
Initial dose: 7.5 mg orally once a day at bedtime
Maintenance dose: 7.5 to 15 mg orally once a day at bedtime
Comments:
- Prolonged administration is not recommended.
- The dose may be increased to 15 mg orally at bedtime if necessary for efficacy.
- The lowest effective dose should be used as adverse effects are dose related.
Use: Treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
Elderly and/or debilitated patients: Start at the lower end of the dosing range and observe closely.
Precautions
US BOXED WARNINGS:
RISKS FROM CONCOMITANT USE WITH OPIOIDS:
- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
- Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs/symptoms of respiratory depression and sedation.
Safety and efficacy have not been established in pediatric patients.
Consult WARNINGS section for additional precautions.
US Controlled Substance: Schedule IV
Dialysis
Data not available
Other Comments
General:
- Efficacy was established in placebo-controlled clinical studies performed in patients with acute and chronic insomnia over 5 nights.
- Sustained efficacy in patients with chronic insomnia was established in a polysomnographic study over 28 nights.
Patient Advice:
- Patients should be instructed to seek medical attention if hypersensitivity reactions occur.
- Patients should be counseled to report new/unusual changes in thinking or behavior or worsening of depression.
- Advise patients of next-day impairment, even in the absence of symptoms; patients should be cautioned that impairment may persist for several days following discontinuation.
- Patients and caregivers of those who are taking concomitant opioid therapy should be told to immediately report profound central nervous system or respiratory depression.